Company Overview
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
Why Investors Should Care
Generates a return on equity of 148.8%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $200.00K (-41.5% YoY); net profit $-26.17M.
- Trailing 12 Months Year-on-year growth — revenue +233.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -0.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -0.59% |
| 1 Year: | 233.30% |
Stock Price Performance
| 1 Year: | -0.82% |
| 6 Months: | -34.06% |
| 3 Months: | -32.08% |
| 1 Month: | -31.44% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)28.49 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 148.8%.
CONS
- Revenue declined at -0.6% CAGR over 5 years.
- Trading 71.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CLNN Clene Inc. | 3.62 | -1.02 | $46.51M | 0.00% | - | 148.78% | -0.59% | - |
| 2 | WMT Walmart Inc. SPXR3K | 107.14 | 38.82 | $850.02B | 0.93% | 16.83% | 22.31% | 3.82% | 3.24% |
| 3 | COST Costco Wholesale Corporation NDXSPXR3K | 910.18 | 45.88 | $403.65B | 0.65% | 25.96% | 29.15% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPXR3K | 88.36 | 26.53 | $380.17B | 2.41% | 16.47% | 42.05% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPXR3K | 145.58 | 21.99 | $338.39B | 2.95% | 22.49% | 30.29% | 0.52% | 1.59% |
| 6 | PM Philip Morris International Inc. SPXR3K | 184.73 | 25.37 | $287.92B | 3.09% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPXR3K | 138.45 | 18.15 | $189.12B | 4.43% | 15.41% | 51.51% | 4.93% | 2.11% |
| 8 | BUD Anheuser-Busch InBev SA/NV | 79.73 | 17.18 | $139.30B | 1.69% | 8.49% | 11.39% | 0.88% | 4.63% |
| 9 | BTI British American Tobacco p.l.c. | 55.15 | 14.18 | $118.73B | 5.98% | 12.44% | 13.42% | -2.53% | 5.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.00K | 9.00K | 98.00K | 213.00K | 201.00K | 110.00K | 30.00K | 35.00K | 174.00K | 107.00K | 269.00K | 108.00K | 73.00K | 91.00K | 87.00K | 81.00K | 27.00K | 15.00K | 15.00K |
| Operating Income | -4.00M | -4.56M | -5.69M | -11.70M | -13.78M | -10.45M | -13.34M | -13.60M | -9.80M | -10.73M | -10.34M | -9.54M | -9.23M | -7.39M | -7.82M | -4.08M | -5.86M | -5.65M | -2.06M |
| Net Income | -3.94M | -5.82M | -10.29M | -39.76M | -3.35M | 28.94M | -13.35M | -4.53M | -10.98M | -11.77M | -25.14M | -2.42M | -11.08M | -6.79M | -7.99M | -751.00K | -7.42M | -8.78M | -8.09M |
| Diluted EPS | - | - | -0.59 | - | -0.05 | 0.42 | - | -0.07 | -0.17 | - | - | - | - | - | - | - | - | - | - |
| R&D Expense | 3.20M | 3.55M | 3.99M | 6.28M | 6.47M | 6.15M | 8.58M | 9.17M | 6.40M | 7.39M | 6.62M | 5.97M | 5.87M | 4.15M | 4.47M | 1.48M | 3.51M | 3.51M | 329.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 206.00K | 723.00K | 473.00K | 654.00K | 342.00K | 200.00K |
| Operating Income | -16.33M | -20.21M | -49.98M | -48.41M | -40.54M | -33.09M | -23.08M |
| Net Income | -16.16M | -19.28M | -9.74M | -29.92M | -49.50M | -39.40M | -26.17M |
| R&D Expense | 9.56M | 15.20M | 28.42M | 31.92M | 26.66M | 20.06M | 14.01M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 14.88M | 68.24M | 63.06M | 44.49M | 52.34M | 27.34M | 18.13M |
| Total Equity | -52.04M | -67.77M | 341.00K | 12.60M | 3.24M | 13.39M | -8.86M | -17.59M |
| Cash & Equivalents | - | 8.79M | 59.27M | 50.29M | 18.33M | 28.82M | 12.15M | 5.19M |
| Long Term Debt | - | - | - | - | - | - | - | 17.79M |
| Total Liabilities | - | 9.99M | 67.90M | 50.47M | 41.26M | 38.95M | 36.19M | 35.72M |
| Current Liabilities | - | 4.31M | 11.67M | 6.03M | 13.86M | 25.33M | 10.29M | 10.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.20M | -18.93M | -34.62M | -39.01M | -30.17M | -21.33M | -18.55M |
| Investing Cash Flow | -294.00K | -387.00K | -1.33M | -10.16M | -1.50M | 6.32M | -39.00K |
| Financing Cash Flow | 5.50M | 69.53M | 27.11M | 17.25M | 42.16M | -1.53M | 11.52M |
| Capital Expenditure | -294.00K | -387.00K | -1.33M | -5.18M | -330.00K | -15.00K | -39.00K |
| Free Cash Flow | -13.49M | -19.32M | -35.96M | -44.19M | -30.50M | -21.34M | -18.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | -9,812.6% | -6,912.6% | -10,234.5% | -6,198.8% | -9,676.3% | -11,541.5% |
| Net Margin % | - | -9,357.8% | -1,347.2% | -6,325.2% | -7,569.4% | -11,520.5% | -13,086.5% |
| ROE % | 23.8% | -5,653.1% | -77.3% | -924.3% | -369.7% | 444.8% | 148.8% |
| ROCE % | -154.6% | -35.7% | -87.6% | -158.0% | -150.1% | -194.1% | -313.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Empery Asset Management, LP | 7.05% | 916.53K | $3.99M |
| 2 | Scoggin Management, LP | 4.62% | 600.00K | $2.61M |
| 3 | Boxer Capital Management, LLC | 3.67% | 477.51K | $2.08M |
| 4 | SymBiosis Capital Partners, LLC | 3.32% | 431.09K | $1.88M |
| 5 | Ensign Peak Advisors, Inc | 2.68% | 348.06K | $1.51M |
| 6 | Vanguard Capital Management LLC | 2.57% | 333.71K | $1.45M |
| 7 | Geode Capital Management, LLC | 0.79% | 102.22K | $444.63K |
| 8 | Blackrock Inc. | 0.47% | 61.56K | $267.78K |
| 9 | Vanguard Fiduciary Trust Co | 0.44% | 57.77K | $251.28K |
| 10 | Lunt Capital Management, Inc. | 0.40% | 52.26K | $227.33K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLNN
Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPMFR5MXROXzRDSHNZSkxfRXhCNlF0MjQzdzRXWUVUWDhlR1BvOE1mdzctYkxuY0hxZEdYaGJrd28tQWk5VlZWNmtEemR0QXNGU3dWY0gxdlFOaEVYSVppcU14TzZYNFVkSTFxbUl5UHl3eWhuUUw5Rl9RZTVKSkIzRmlwQ25pelZwZHVtNk…
Two investor conferences in New York will hear from Clene this month - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPYVRUME9FUnNyd0xzQWZKSVdSX24tSVZULVFRWWFQckxqRmlNc3NIRG0wMTJjdGRVek9BckF6VzMzNDBHeEEzdkRpX0hMeFBYWm1rTVpmWFd3SFVaaFYtS20yWUU2ODdaRHU2VGJFekMxX1JWcDlCU3pEZTFZSTVjeUY3blpTSEQ5RGpTel…
CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’ - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPbm9LTGVWR3h5MER4UGc3QW1hdUYtd1lxaXZMbWR6SURrNlBreXp6anJmdl90VDZ3YlhWX3hHZERBTXlaRTFsM09HaXFCZnNxMjFyRUt2c2Y1M0JGZW0zZ2VRRmh4cGx3QTloWjZxREU5dFQxVTBVU3U4dFVTTS00eFZkNjY4bkZBZzEwVD…
$CLNN stock is down 14% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNbDZfd2dKUjcyVFJWVTMtczhpMjdMUEdmTzVkc0pRWUp5bVpYNlRuVGoweUdJWlZxcmtlVGRvVjkwbnZsQkxqMk1JM2NFVjVsWnBUcjlJaTNGZGU5REc3cUI5eFpwR29YNTU0d1NxUHNoMWhWWUNLSXgweWZIX0lZeXgtMS1YeGFjRGIzOH…
CLNN Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFB5eXE0Ti1XVUVidzgyR2h6SXBwRWhxNWFUU2hMN0haOUpIVU5rSUdBcExhX1lLUDNHc05EM3FiT3BfRVZHVU9melN3Qms4TWdyWUJzWGVPYVBUX0NfaUFwMXpsZGV0ODh6MEZ0RWgyWGE2SWV5aVI2SW1B?oc=5" target="_blank">CLN…
CLNN - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1RSWxNaS1Edi1hUGZoY0hXb0JjeXJjWmRZR0VhS2NWMmpPUURRWGFzNjhaRF84T1hySjg4Y01uWHZ1N2o3TkE?oc=5" target="_blank">CLNN</a> <font color="#6f6f6f">Finviz</font>…
CLNN — Frequently Asked Questions
What is the current share price of Clene Inc. (CLNN)?
As of 2026-09-19 21:16 PDT, Clene Inc. (CLNN) trades at $3.62 on NasdaqCM. Its 52-week range is $3.60 to $12.50.
What is the market capitalisation of CLNN?
Clene Inc. (CLNN) has a market capitalisation of $46.51M on NasdaqCM.
What is the P/E ratio of CLNN?
CLNN trades at a trailing price-to-earnings (P/E) ratio of -1.02. The industry average P/E is 18.56. Its price-to-book (P/B) ratio is -1.92.
What is the return on equity (ROE) of CLNN?
CLNN has a return on equity (ROE) of 148.78%.
Is CLNN a good stock to buy?
This page provides a data-driven analysis of Clene Inc. (CLNN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.